Validation of variants inSLC28A3andUGT1A6as genetic markers predictive of anthracycline-induced cardiotoxicity in children

Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children

(2011) Henk Visscher et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiac Function in 5-Year Survivors of Childhood Cancer

(2010) Helena J. van der Pal et al.   ARCHIVES OF INTERNAL MEDICINE

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Role of Cancer Treatment in Long-Term Overall and Cardiovascular Mortality After Childhood Cancer

(2010) Markhaba Tukenova et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21

(2009) D Rossi et al.   LEUKEMIA

Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood

(2009) Vladan Rajić et al.   LEUKEMIA & LYMPHOMA

Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals

(2009) BC Carleton et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Application of principal component analysis to pharmacogenomic studies in Canada

(2009) H Visscher et al.   PHARMACOGENOMICS JOURNAL

Genetic polymorphisms in the carbonyl reductase 3 geneCBR3 and the NAD(P)H:quinone oxidoreductase 1 geneNQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer

(2008) Javier G. Blanco et al.   CANCER

SLC28 genes and concentrative nucleoside transporter (CNT) proteins

(2008) M. Pastor-Anglada et al.   XENOBIOTICA